Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10503241 | 0.80 | TAAR1 (0.67) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL5409507 | 0.80 | TAAR1 (0.54) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL5408804 | 0.78 | TAAR1 (0.52) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL185769 | 0.78 | SLC6A2 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL19224281 | 0.78 | SLC6A2 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL4081566 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL583541 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL352842 | 0.78 | TAAR1 (0.64) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| SCHEMBL21243975 | 0.77 | SMN1; SMN2 (0.50) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 | |
| Water SCHEMBL8366271 | 0.76 | TAAR1 (0.61) | TAAR1SLC6A2SMN1; SMN2HIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030110-B2 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1303510-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1259506-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6476016-B2 | INHIBITING LOSS OF BLOOD PLATELETS, INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, INHIBITING FORMATION OF FIBRIN, INHIBITING THROMBUS FORMATION, AND INHIBITING EMBOLUS FORMATION | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-6387911-B1 | Pyrazinone thrombin inhibitors | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002006248-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-5763465-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1998-06-09 | — | — | US | disclosed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052357-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | TAAR1 1263/4885SLC6A2 3879/4885SMN1; SMN2 4082/4885 |
| US-20030073702-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, SERPINE1, TFPI | TAAR1 1263/4885SLC6A2 3879/4885SMN1; SMN2 4082/4885 |
| US-20060058291-A1 | Cyclic oxyguanidine pyrazinones as protease inhibitors | PLG, TFPI, F12 | TAAR1 1415/4885SLC6A2 3288/4885SMN1; SMN2 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.